KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Common Equity (2016 - 2026)

Bio-Rad Laboratories has reported Common Equity over the past 18 years, most recently at $6.9 billion for Q1 2026.

  • Quarterly Common Equity rose 2.57% to $6.9 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.9 billion through Mar 2026, up 2.57% year-over-year, with the annual reading at $7.5 billion for FY2025, 13.46% up from the prior year.
  • Common Equity was $6.9 billion for Q1 2026 at Bio-Rad Laboratories, down from $7.5 billion in the prior quarter.
  • Over five years, Common Equity peaked at $10.2 billion in Q1 2022 and troughed at $6.6 billion in Q4 2024.
  • The 5-year median for Common Equity is $8.4 billion (2023), against an average of $8.1 billion.
  • Year-over-year, Common Equity crashed 44.71% in 2022 and then increased 13.46% in 2025.
  • A 5-year view of Common Equity shows it stood at $9.6 billion in 2022, then decreased by 9.09% to $8.7 billion in 2023, then dropped by 24.85% to $6.6 billion in 2024, then increased by 13.46% to $7.5 billion in 2025, then decreased by 8.08% to $6.9 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Common Equity are $6.9 billion (Q1 2026), $7.5 billion (Q4 2025), and $6.7 billion (Q3 2025).